You are using an unsupported browser.

Some features of this site may not function properly. For optimal user experience, please view this site in Chrome, Firefox, Safari, or Edge.

Sorry, your browser window is too small.

Some features of this site may not function properly. For optimal user experience, please view this site in a larger browser window.

For US Healthcare ProfessionalsFor US HCPs

GSK Vaccination

Tell us what you are looking for in the search box.

Image: Patient showing pharmacist information on cell phone

Image: Patient showing pharmacist information on cell phone

MENINGOCOCCAL SEROGROUPS A, B, C, W, & Y

Meningococcal disease is an uncommon—although serious and potentially life-threatening—infection, which is spread through close contact such as coughing, kissing, or sneezing. Symptoms including sudden onset of high fever, headache, neck stiffness, nausea, and vomiting can progress rapidly and may lead to death.^1-4

Facts About Meningococcal Disease

One out of ten patients infected will die, some in as few as 24 to 48 hours.¹

Surviving patients may face long-term complications such as hearing loss, brain damage, limb loss, kidney failure, and seizures.^4,5

Most meningococcal disease is attributed to serogroups A, B, C, W, and Y.²

Meningococcal Vaccination Recommendations

Image: Injecting meningococcal vaccine

Meningococcal Vaccination Recommendations From the Centers for Disease Control and Prevention (CDC)

Meningococcal ACWY:

Persons 11 years of age and older, with a booster at 16 years of age; as young as 2 months of age for certain groups at increased risk⁶

Meningococcal B:

Vaccination recommended for certain groups at increased risk in individuals 10 years of age and older⁶
In individuals not at increased risk, MenB series for persons 16 to 23 years of age (preferably 16 to 18 years of age) on the basis of shared clinical decision-making⁷

Meningococcal Disease Downloadable Resources

Patient Resources
Pharmacist Resources

What you need to know about meningococcal B vaccine

Information Statement

Meningitis B Vaccine Information Sheet (CDC)

Thumbnail: Meningococcal B website

Website

Meningitis Website

Meningococcal Patient Brochure Spanish

Brochure

Patient Education Brochure (Spanish)

Download Meningococcal Disease Pharmacist Resources

References

Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46:S9-S15.
McNamara LA, Blain A. Meningococcal disease. In: Roush SW, Baldy LM, Kirkconnell Hall MA, eds. Manual for the Surveillance of Vaccine-Preventable Diseases. Centers for Disease Control and Prevention; 2020. Reviewed January 5, 2022. Accessed January 30, 2024. https://www.cdc.gov/vaccines/pubs/surv-manual/chpt08-mening.html
Meningococcal disease: signs and symptoms. Centers for Disease Control and Prevention. Revised February 7, 2022. Accessed January 30, 2024. https://www.cdc.gov/meningococcal/about/symptoms.html
Meningitis. Mayo Clinic. Updated October 4, 2023. Accessed January 30, 2024. https://www.mayoclinic.org/diseases-conditions/meningitis/symptoms-causes/syc-20350508
Meningococcal disease: clinical information. Centers for Disease Control and Prevention. Reviewed February 7, 2022. Accessed January 30, 2024. https://www.cdc.gov/meningococcal/clinical-info.html
Child and adolescent immunization schedule by age, 2023. Centers for Disease Control and Prevention. Reviewed November 16, 2023. Accessed January 30, 2024. https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html
Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR. 2020;69(No. RR-9):1-41. Reviewed September 24, 2020. Accessed January 30, 2024. https://www.cdc.gov/mmwr/volumes/69/rr/rr6909a1.htm?s_cid=rr6909a1_w

Trademarks are owned by or licensed to the GSK group of companies.